Date: 2017-01-05
Type of information: Research agreement
Compound: bispecific antibodies targeting the microenvironnement
Company: Merus (The Netherlands) IRB Barcelona (Spain)
Therapeutic area: Cancer - Oncology
Type agreement: research
Action mechanism: bispecific antibody
Disease:
Details:
- • On January 5, 2017, Merus and the Institute for Research in Biomedicine (IRB) Barcelona announced entry into a research collaboration to jointly develop novel agents that target the tumor microenvironment. The research collaboration will combine Merus’ Biclonics technology platform for the discovery and development of therapeutic bispecific antibodies and IRB’s cell and animal models to evaluate therapeutic targeting of stromal cells that support tumor growth and metastasis.
- “This new research collaboration builds on the successful working relationship established in the suppresSTEM consortium that resulted in MCLA-158, a Biclonics targeting EGFR and Lgr5 that is currently in IND-enabling studies,” said Mark Throsby, Chief Scientific Officer of Merus.
Financial terms:
Latest news:
Is general: Yes
